

#### SCOPE OF THE CLAIM

1. An oral solid dosage form having  
(S)-2-[3-[N-[4-(4-fluorophenoxy)benzyl]carbamoyl]-4-methoxybenzyl]butanoic acid (hereinafter abbreviated as KRP-101) as an effective ingredient and comprising KRP-101 and additives.
2. The oral solid dosage form of Claim 1, wherein the additives comprise excipient, disintegrator and lubricant, or these and coating agent.
3. The oral solid dosage form of Claim 1 or 2, wherein the excipient comprises lactose and/or microcrystalline cellulose, the disintegrator comprises low substituted hydroxypropylcellulose, the lubricant comprises magnesium stearate, and the coating agent comprises hydroxypropylmethylcellulose and/or carnauba wax.
4. The oral solid dosage form of any of Claim 1 through 3, wherein, to a mixed powder obtained by repeating a plurality of steps of mixing and dilution of KRP-101 with excipient, the excipient, disintegrator and lubricant are added and the mixed powder with less than 1% of KRP-101 is granulated.